Related Experiment Videos
[Beta-blocking drugs indicated in patients with heart failure]
A A Voors1, W H van Gilst, D J van Veldhuisen
1Thoraxcentrum, afd. Cardiologie, Academisch Ziekenhuis, Postbus 30.001, 9700 RB Groningen. a.a.voors@thorax.azg.nl
Nederlands Tijdschrift Voor Geneeskunde
|January 8, 2004
Summary
Beta-blockers are now recommended for chronic heart failure. Carvedilol showed a 17% mortality reduction compared to metoprolol, though further research is needed to confirm superiority in heart failure management.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Beta-blocking drugs were historically contraindicated in chronic heart failure.
- Recent clinical trials have established the efficacy of beta-blockers in heart failure.
- Uncertainty remained regarding the comparative efficacy of nonselective (carvedilol) versus selective (metoprolol) beta-blockade.
Purpose of the Study:
- To compare the efficacy of carvedilol (nonselective alpha-, beta 1-, and beta 2-receptor blockade) versus metoprolol (selective beta 1-receptor blockade) in patients with chronic heart failure.
- To evaluate the impact of carvedilol on all-cause mortality and myocardial function in heart failure patients.
Main Methods:
- The study references the 'Carvedilol or metoprolol European trial' (COMET) and the 'Carvedilol hibernation reversible ischaemia trial; marker of success' (CHRISTMAS).
- COMET compared carvedilol and metoprolol, assessing all-cause mortality.
- CHRISTMAS investigated carvedilol's effects on myocardial hibernation and left-ventricle function in ischaemic heart failure.
Main Results:
- The COMET trial demonstrated a statistically significant 17% reduction in all-cause mortality with carvedilol compared to metoprolol.
- Potential confounding factors in COMET results include differences in blood pressure, heart rate, and the formulation of metoprolol used.
- The CHRISTMAS study showed carvedilol improved left-ventricle function in both hibernated and non-hibernated ischaemic heart failure patients.
Conclusions:
- Carvedilol demonstrated a significant survival benefit in the COMET trial, although potential confounding factors warrant consideration.
- Carvedilol exhibits beneficial effects on myocardial function, including in cases of hibernation, as shown in the CHRISTMAS study.
- Despite strong evidence, a minority of eligible chronic heart failure patients are currently treated with beta-blockers, indicating a gap in clinical practice.